Farzaneh Rostami

Aureocin A53 as a therapeutic agent against drug-resistant mycobacteria including M. tuberculosis and non-tuberculous strains

The global rise of tuberculosis (TB) and increasing drug resistance in Mycobacterium tuberculosis ( M. tuberculosis ) highlight the urgent need for novel antimycobacterial agents. Antimicrobial peptides (AMPs), particularly bacteriocins, offer promising therapeutic options or adj...